Amifostine

• Radiation-Protective Agents
• ATC:V03AF05

• Amifostine Ethiofos
• Aminopropylaminoethyl Thiophosphate
• Apaetp
• Ethiofos
• Ethyol
• Gammaphos
• SAPEP

• No information avaliable

C₅H₁₅N₂O₃PS

http://www.rxlist.com/cgi/generic/amifostine.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=118

Amifostine MSDS

No information avaliable

214.224 g/mol

No information avaliable

1000 mg/mL

Solid

-1.043

Powder for solution

For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.

Amifostine is an organic thiophosphate cytoprotective agent indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer and also to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite, believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.

No information avaliable

Rat LD₅₀: 826 mg/kg

No information avaliable

Humans and other mammals